All News
Filter News
Found 101 articles
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
-
Flagship began raising the funds in January, and closed on it late last week.
-
One of the key takeaways from BIO-Europe Spring 2020 was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
-
Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis
3/23/2020
- In the months since the global public health crisis rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. The crisis has catalyzed the development of novel vaccines across
-
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...
-
Inside the U.S., the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 began today.
-
Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
3/16/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
-
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
-
Biopharma companies, government regulatory and health agencies and academic centers are stepping forward and working to test or develop vaccines and therapeutics for the disease.
-
According to a Wall Street Journal report, Takeda has assigned about 40 staffers to work on the project, which was only conceptual a few weeks ago until they triggered the program.
-
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
-
As Coronavirus Threat Continues, Biopharma and Academia Gear Up to Test and Develop Vaccines and ...
2/26/2020
The U.S. Centers for Disease Control and Prevention warned the public yesterday to be prepared for it to spread in the U.S., indicating it was “when,” not “if.” -
As the number of cases and deaths continues to increase in China and around the world, Moderna shipped its first batch of mRNA-1273, a vaccine against the virus, for a planned Phase I clinical trial in the U.S.
-
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
-
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name, COVID-19.
-
Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates
2/10/2020
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020.